Proposition - PharmXpert Academy

More documents

Recommendations

Info

The Korean Pharmaceutical Company List 537 71. WhanIn Pharm Co., Ltd. 1. Company Information Company WhanIn Pharm Co., Ltd. Representative Kye-Kwan Lee E-mail webmaster@whanin.com Representative Phone No. Hompage 82-2-405-3000 www.whanin.com Representative Fax No. 82-2-405-2518 Address 84-1, Moonjung-dong, Songpa-ku, Seoul, 138-200, Korea Research Institute Address Year of Establishment The Number of Employees (06‘) 906-5, Iui-dong, Yeongton-gu, Suwon, Gyeonggi-do, 443-766, Korea 1978 Sales (‘06) 73 Million$ Total The Number of 322 Researcher (‘06) 21 Total Contact Person Soo-Jin Kang Contact Phone 82-2-405-3063 Contact E-mail ksjin@whanin.com Contact Fax 82-2-405-3182 Introduction of Company WhanIn Pharmaceutical Co., Ltd. is a publicly held Korean pharmaceutical company that develops, markets, manufactures and sells the therapeutic products for the treatment of CNS disorders, bone related disease such as osteoporosis, pain management and aging related disorders. Founded in 1978, WhanIn originally focused on the psychiatric and neurological diseases. Recognizing new opportunities in CNS disorders, WhanIn is concentrating on bringing the new products and technologies for the patients suffering from such CNS disorders. During the past quarter of century in the healthcare professionals and Korean community, WhanIn is engraved as one of the best local pharmaceuticals company to dedicate in supplying the social and medical communities with the quality products. WhanIn is expanding its product portfolio to become a leading specialty pharmaceutical company in the important therapeutic segments in healthcare market. The company has state-of-the-art manufacturing facilities located in Ansung city and owns research and development center capable of developing the value-added products based on own platform pharmaceutical drug delivery technologies. Headquarter is located in Seoul, Korea. WhanIn is pursuing to be flexible, aggressive and cooperative in discussing mutual business collaboration with our potential licensors and collaborators in worldwide healthcare market. Mutual collaboration and business partnership are the most valuable asset and core competency for preparing future common goals.
538 2007 Korea Pharmaceutical Industry Directory 2. Main Products Information No. The Name of Products 1 Alpram Alprazolam 2 Riperidone Risperidone 3 U-rantac Ranitidine HCl Main Ingredient Use (Indications) Formulation 1) The management of anxiety disorder or short term relief of symptoms of anxiety. 2) Anxiety associated with depression 3) Anxiety, tension, depression, sleep disorder in psychosomatic disorder 4)Panic disorder 1) Acute and chronic schizophrenia, other psychiatric disorder, affective disorder associated with schizophrenia 2) Aggressiveness, activity disorder and activity disorder of dementia patient with psychiatric disorder 3) Adjunctive therapy of mood stabilizer for treatment of mania associated with bipolar disorder 4) Children, juveniles with mental retardation having prominent destructive behavior or with subpar inellectual faculty, conduct disorder and other destructive activity disorder of adults 1) Gastric hyperacidity, Heartburn 2) Gastroduodenal ulcer, Zollinger-Ellison syndrome, reflux oesophagitis, preanesthetic(prevention of Mendelson's syndrome), postoperative ulcer, Gastroduodenal ulcer associated with NSAIDs 3)Acute gastritis, acute exacerbation of chronic gastritis, upper alimentary tract bleeding(by peptic ulcer, acute stress ulcer, acute Gastric mucosal disorder) 4 Neuleptol Gabapentin Epilepsy, neuropathic pain 5 Grandaxin Tofisopam 6 Alend Sodium alendronate Autonomic nervous symptoms such as headache, malaise, palpitation, sweating accompanied with dysautonomia, head and cervical injuries, menopausal disorder ․ anovaria Treatment and prevention of osteoporosis in postmenopausal women Treatment of glucocorticoid-induced osteoporosis in men and women The Date of Sales Tablet 89.10.01 Tablet 03.07.01 Tablet/ Injection Tablet/ Capsule 89.10.01 04.09.01 Tablet 98.11.01 Expected Exporting Countries Etc.
Page 2 and 3:
2007 Korea Pharmaceutical Industry
Page 4 and 5:
2007 Korea Pharmaceutical Industry
Page 6 and 7:
27. ILYANG PHARM ·········
Page 8 and 9:
Chapter 1. Outline of The Project 2
Page 10 and 11:
Chapter 1. Outline of The Project 2
Page 12 and 13:
Chapter 2. Pharmaceutical Industry
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
The Annex
Page 38 and 39:
316 2007 Korea Pharmaceutical Indus
Page 40 and 41:
The Korean Pharmaceutical Company L
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
4. Company Map The Korean Pharmace
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209: The Korean Pharmaceutical Company L
Page 254 and 255: 3. Company Map The Korean Pharmace
show all

Proposition - PharmXpert Academy

Create successful ePaper yourself

Delete template?

Save as template?